| scholarly article | Q13442814 |
| P50 | author | Fred Gage | Q895547 |
| Alysson Muotri | Q16489352 | ||
| Maria C N Marchetto | Q99353490 | ||
| P2093 | author name string | Gabriela G Cezar | |
| Yangling Mu | |||
| Alan M Smith | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | astrocyte | Q502961 |
| human embryonic stem cell | Q59626782 | ||
| P304 | page(s) | 649-657 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Cell Stem Cell | Q2943975 |
| P1476 | title | Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells | |
| P478 | volume | 3 |
| Q64269328 | A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS |
| Q28543975 | A comprehensive library of familial human amyotrophic lateral sclerosis induced pluripotent stem cells |
| Q28080614 | A perspective on stem cell modeling of amyotrophic lateral sclerosis |
| Q39432513 | A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. |
| Q26774824 | ALS Patient Stem Cells for Unveiling Disease Signatures of Motoneuron Susceptibility: Perspectives on the Deadly Mitochondria, ER Stress and Calcium Triad |
| Q67471897 | Aberrant calcium signaling in astrocytes inhibits neuronal excitability in a human Down syndrome stem cell model |
| Q28482371 | Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase |
| Q37555038 | Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis |
| Q33729764 | Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis |
| Q38160415 | Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis. |
| Q66679557 | All Together Now: Modeling the Interaction of Neural With Non-neural Systems Using Organoid Models |
| Q35562672 | Alsin and SOD1(G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity |
| Q33671504 | Altered Metabolic Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures. |
| Q55003224 | Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors. |
| Q38160421 | Amyotrophic lateral sclerosis and skeletal muscle: an update. |
| Q40882269 | Amyotrophic lateral sclerosis model derived from human embryonic stem cells overexpressing mutant superoxide dismutase 1. |
| Q33796347 | Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms |
| Q48217709 | Amyotrophic lateral sclerosis-related mutant superoxide dismutase 1 aggregates inhibit 14-3-3-mediated cell survival by sequestration into the JUNQ compartment |
| Q38160459 | Amyotrophic lateral sclerosis: applications of stem cells - an update. |
| Q41327539 | An Efficient Platform for Astrocyte Differentiation from Human Induced Pluripotent Stem Cells |
| Q92569370 | An update on human astrocytes and their role in development and disease |
| Q36246294 | Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death |
| Q45118943 | Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. |
| Q30537986 | Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. |
| Q45971848 | Astrocyte-neuron co-culture on microchips based on the model of SOD mutation to mimic ALS. |
| Q38715282 | Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy |
| Q35471228 | Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo |
| Q37564322 | Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress |
| Q35206666 | Astrocytes from familial and sporadic ALS patients are toxic to motor neurons |
| Q52092430 | Astrocytes in a dish: Using pluripotent stem cells to model neurodegenerative and neurodevelopmental disorders. |
| Q38422519 | Astrocytes in neurodegenerative disease |
| Q37692680 | Astroglial cells regulate the developmental timeline of human neurons differentiated from induced pluripotent stem cells |
| Q37794395 | Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes |
| Q89848904 | Bidens pilosa Extract Administered after Symptom Onset Attenuates Glial Activation, Improves Motor Performance, and Prolongs Survival in a Mouse Model of Amyotrophic Lateral Sclerosis |
| Q38104829 | Bioengineered stem cells in neural development and neurodegeneration research |
| Q37861394 | Biomedical and social contributions to sustainability. |
| Q64072244 | CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons |
| Q37922212 | Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges |
| Q59335768 | Cell-Biological Requirements for the Generation of Dentate Gyrus Granule Neurons |
| Q64978877 | Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans. |
| Q37954112 | Cellular reprogramming: a new technology frontier in pharmaceutical research |
| Q38150127 | Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis |
| Q48304843 | Chronic infusion of SOD1G93A astrocyte-secreted factors induces spinal motoneuron degeneration and neuromuscular dysfunction in healthy rats. |
| Q28077853 | Common pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and research |
| Q42264202 | Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis |
| Q26863439 | Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis |
| Q39036105 | Could Sirtuin Activities Modify ALS Onset and Progression? |
| Q26861926 | Current concept in neural regeneration research: NSCs isolation, characterization and transplantation in various neurodegenerative diseases and stroke: A review |
| Q38590664 | Current status of pluripotent stem cells: moving the first therapies to the clinic. |
| Q34257147 | Cytotoxicity of superoxide dismutase 1 in cultured cells is linked to Zn2+ chelation |
| Q36293324 | Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons. |
| Q39004348 | Decoding ALS: from genes to mechanism. |
| Q37010269 | Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice |
| Q36903049 | Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS. |
| Q91259886 | Differentiation and maturation of oligodendrocytes in human three-dimensional neural cultures |
| Q38884808 | Differentiation of Human Neural Stem Cells into Motor Neurons Stimulates Mitochondrial Biogenesis and Decreases Glycolytic Flux |
| Q38218082 | Directed midbrain and spinal cord neurogenesis from pluripotent stem cells to model development and disease in a dish |
| Q38107799 | Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells |
| Q36267735 | Distinct repertoires of microRNAs present in mouse astrocytes compared to astrocyte-secreted exosomes |
| Q89629404 | Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis |
| Q47929663 | Diversity of astroglial responses across human neurodegenerative disorders and brain aging |
| Q35175041 | Downregulation of VAPB expression in motor neurons derived from induced pluripotent stem cells of ALS8 patients |
| Q42175982 | Drug discovery models and toxicity testing using embryonic and induced pluripotent stem-cell-derived cardiac and neuronal cells |
| Q42820289 | Drug screening for ALS using patient-specific induced pluripotent stem cells |
| Q58694151 | Dysregulation of Astrocytic HMGB1 Signaling in Amyotrophic Lateral Sclerosis |
| Q36290454 | Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene Inhibition |
| Q38034476 | Embryonic and induced pluripotent stem cell differentiation as a tool in neurobiology |
| Q37579376 | Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling |
| Q36708477 | Enhanced aggregation of androgen receptor in induced pluripotent stem cell-derived neurons from spinal and bulbar muscular atrophy |
| Q38838046 | Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience |
| Q37823334 | Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials |
| Q97066870 | Exciting Complexity: The Role of Motor Circuit Elements in ALS Pathophysiology |
| Q33980768 | Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. |
| Q34450040 | FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels |
| Q37705035 | Flavonoids and astrocytes crosstalking: implications for brain development and pathology. |
| Q99723633 | Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease |
| Q96123053 | GLAST-CreERT2 mediated deletion of GDNF increases brain damage and exacerbates long-term stroke outcomes after focal ischemic stroke in mouse model |
| Q30659873 | Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. |
| Q38975150 | Generating human serotonergic neurons in vitro: Methodological advances. |
| Q41463975 | Generation of GFAP::GFP astrocyte reporter lines from human adult fibroblast-derived iPS cells using zinc-finger nuclease technology |
| Q47732172 | Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q10 Deficiency. |
| Q51064372 | Genetic validation of a therapeutic target in a mouse model of ALS. |
| Q92813735 | Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment |
| Q38908720 | Glial Na(+) -dependent ion transporters in pathophysiological conditions. |
| Q37902077 | Glial cells in amyotrophic lateral sclerosis |
| Q33687971 | Global gene expression profiling of somatic motor neuron populations with different vulnerability identify molecules and pathways of degeneration and protection |
| Q37290026 | Growth factor-expressing human neural progenitor cell grafts protect motor neurons but do not ameliorate motor performance and survival in ALS mice. |
| Q48106083 | Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. |
| Q34182222 | Harnessing the potential of induced pluripotent stem cells for regenerative medicine |
| Q33496139 | Highly efficient differentiation and enrichment of spinal motor neurons derived from human and monkey embryonic stem cells |
| Q39441131 | Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. |
| Q91581219 | Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity |
| Q37776428 | Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells |
| Q27324779 | Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation |
| Q37931912 | Human pluripotent stem cells for genetic disease modeling and drug screening. |
| Q36193696 | Human pluripotent stem cells: applications and challenges in neurological diseases. |
| Q38057758 | Human stem cell-derived astrocytes and their application to studying Nrf2-mediated neuroprotective pathways and therapeutics in neurodegeneration |
| Q41040870 | Human stem cells as a model of motoneuron development and diseases |
| Q35183893 | Human-derived neural progenitors functionally replace astrocytes in adult mice. |
| Q38211417 | Human-induced pluripotent stem cells pave the road for a better understanding of motor neuron disease |
| Q35092672 | IFNγ triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1. |
| Q38123758 | Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis |
| Q26799285 | Importance of being Nernst: Synaptic activity and functional relevance in stem cell-derived neurons |
| Q27345537 | In vitro myelin formation using embryonic stem cells |
| Q47153099 | In vivo genome editing improves motor function and extends survival in a mouse model of ALS. |
| Q34206028 | Induced pluripotency: history, mechanisms, and applications |
| Q39040578 | Induced pluripotent stem cell technology: a decade of progress |
| Q37914472 | Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises |
| Q27000647 | Induced pluripotent stem cells from ALS patients for disease modeling |
| Q37857439 | Induced pluripotent stem cells: a new revolution for clinical neurology? |
| Q34303709 | Induced pluripotent stem cells: the new patient? |
| Q33664711 | Inflammation in ALS and SMA: sorting out the good from the evil |
| Q37912590 | Inflammation in the early stages of neurodegenerative pathology |
| Q39007648 | Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons |
| Q34431170 | Investigating human disease using stem cell models |
| Q38592446 | Is membrane homeostasis the missing link between inflammation and neurodegenerative diseases? |
| Q61816592 | Key role of SMN/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons |
| Q35365484 | Macrophage migration inhibitory factor as a chaperone inhibiting accumulation of misfolded SOD1. |
| Q41596941 | Macrophage migration inhibitory factor as a component of selective vulnerability of motor neurons in ALS. |
| Q30277241 | Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis |
| Q29617977 | Mechanisms underlying inflammation in neurodegeneration |
| Q92185713 | Membralin deficiency dysregulates astrocytic glutamate homeostasis leading to ALS-like impairment |
| Q30575638 | Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis |
| Q37406411 | Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. |
| Q34103782 | Mitochondrial dysfunction and intracellular calcium dysregulation in ALS |
| Q49601349 | Modeling Neurovascular Disorders and Therapeutic Outcomes with Human-Induced Pluripotent Stem Cells |
| Q38460557 | Modeling hippocampal neurogenesis using human pluripotent stem cells |
| Q39130188 | Modeling neurodevelopmental and psychiatric diseases with human iPSCs |
| Q37897966 | Modeling neurological diseases using patient-derived induced pluripotent stem cells |
| Q30446669 | Modeling psychiatric disorders at the cellular and network levels |
| Q38679839 | Modeling psychiatric disorders with patient-derived iPSCs |
| Q38741408 | Modeling the C9ORF72 repeat expansion mutation using human induced pluripotent stem cells |
| Q28482111 | Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis |
| Q37952528 | Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis |
| Q40133342 | Motor neuron death in ALS: programmed by astrocytes? |
| Q26822886 | Motor neuron derivation from human embryonic and induced pluripotent stem cells: experimental approaches and clinical perspectives |
| Q33665800 | Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis |
| Q92007232 | Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology |
| Q33959395 | Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors |
| Q36813927 | Mutant SOD1 microglia-generated nitroxidative stress promotes toxicity to human fetal neural stem cell-derived motor neurons through direct damage and noxious interactions with astrocytes |
| Q30848992 | Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis |
| Q36890607 | Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis |
| Q37589114 | NADPH oxidase in brain injury and neurodegenerative disorders |
| Q36336772 | NADPH oxidases: novel therapeutic targets for neurodegenerative diseases |
| Q34039826 | Necroptosis drives motor neuron death in models of both sporadic and familial ALS. |
| Q91345013 | Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS |
| Q37737385 | Neurodegenerative disease-specific induced pluripotent stem cell research |
| Q26776339 | Neuroinflammation in motor neuron disease |
| Q35529701 | Neuron-specific antioxidant OXR1 extends survival of a mouse model of amyotrophic lateral sclerosis |
| Q30523191 | Neuronal expression of Fig4 is both necessary and sufficient to prevent spongiform neurodegeneration. |
| Q38701237 | New In Vitro Models to Study Amyotrophic Lateral Sclerosis |
| Q37840172 | New approaches for the generation of induced pluripotent stem cells |
| Q36389277 | New frontiers in human cell biology and medicine: can pluripotent stem cells deliver? |
| Q34288768 | Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent |
| Q34092226 | Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. |
| Q37945678 | Novel paths towards neural cellular products for neurological disorders |
| Q34348268 | Nuclear receptors in stem cells and their therapeutic potential |
| Q35750557 | Opportunities and Limitations of Modelling Alzheimer's Disease with Induced Pluripotent Stem Cells |
| Q34353458 | Opportunities and challenges of pluripotent stem cell neurodegenerative disease models |
| Q27303723 | Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. |
| Q35695531 | Patient-derived olfactory mucosa for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology |
| Q41836711 | Patient-specific pluripotent stem cells in neurological diseases |
| Q96953340 | Peripheral and Central Nervous System Immune Response Crosstalk in Amyotrophic Lateral Sclerosis |
| Q58023563 | Phenotypic heterogeneity of astrocytes in motor neuron disease. |
| Q35518293 | Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis |
| Q38060410 | Pluripotent stem cell for modeling neurological diseases. |
| Q33871319 | Pluripotent stem cells in neurodegenerative and neurodevelopmental diseases. |
| Q36328114 | Polyglutamine (polyQ) disorders: the chromatin connection |
| Q35761135 | Probing disorders of the nervous system using reprogramming approaches |
| Q33559694 | Progress toward the clinical application of patient-specific pluripotent stem cells |
| Q37642955 | Proteasome impairment in neural cells derived from HMSN-P patient iPSCs |
| Q38264328 | Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies |
| Q43410195 | RNA-binding protein QKI regulates Glial fibrillary acidic protein expression in human astrocytes |
| Q34148669 | Rac1 at the crossroad of actin dynamics and neuroinflammation in Amyotrophic Lateral Sclerosis |
| Q35285752 | Rapid and efficient generation of functional motor neurons from human pluripotent stem cells using gene delivered transcription factor codes. |
| Q41325784 | Reactive Astrocytes Promote ALS-like Degeneration and Intracellular Protein Aggregation in Human Motor Neurons by Disrupting Autophagy through TGF-β1. |
| Q35701794 | Reactive oxygen species trigger motoneuron death in non-cell-autonomous models of ALS through activation of c-Abl signaling |
| Q35772134 | Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery |
| Q33742737 | Redox modifier genes and pathways in amyotrophic lateral sclerosis |
| Q36734551 | Reverse engineering human neurodegenerative disease using pluripotent stem cell technology |
| Q41488070 | Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications |
| Q33942366 | Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells. |
| Q35087565 | Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. |
| Q37894600 | SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments |
| Q55412795 | Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models. |
| Q37132752 | Schwann cells expressing dismutase active mutant SOD1 unexpectedly slow disease progression in ALS mice. |
| Q96638742 | Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model |
| Q38059176 | Specification of functional neurons and glia from human pluripotent stem cells |
| Q37614887 | Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production |
| Q33559848 | Sporadic ALS Astrocytes Induce Neuronal Degeneration In Vivo |
| Q33552181 | Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology |
| Q33919781 | Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis |
| Q37761366 | Stem cells and the ALS neurologist |
| Q38341972 | Stem cells for amyotrophic lateral sclerosis modeling and therapy: myth or fact? |
| Q27687068 | Stem cells in human neurodegenerative disorders--time for clinical translation? |
| Q27027574 | Stem cells in the nervous system |
| Q34845881 | Stem cells on the brain: modeling neurodevelopmental and neurodegenerative diseases using human induced pluripotent stem cells |
| Q92378165 | Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models |
| Q49905442 | Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. |
| Q58762401 | Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models |
| Q89741641 | Synaptotagmin 13 is neuroprotective across motor neuron diseases |
| Q101226247 | Systematic elucidation of neuron-astrocyte interaction in models of amyotrophic lateral sclerosis using multi-modal integrated bioinformatics workflow |
| Q24646096 | Targeting neural precursors in the adult brain rescues injured dopamine neurons |
| Q37642100 | Technical challenges in using human induced pluripotent stem cells to model disease |
| Q58589620 | The ALS-inducing factors, TDP43 and SOD1, directly affect and sensitize sensory neurons to stress |
| Q34428986 | The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery |
| Q57732159 | The BH4 domain of Bcl-XL rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals |
| Q47875785 | The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening |
| Q59544567 | The Role of Astrocytes in Parkinson’s Disease |
| Q38722713 | The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders |
| Q26766372 | The Use of Stem Cells to Model Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: From Basic Research to Regenerative Medicine |
| Q42788253 | The evolving biology of cell reprogramming. |
| Q38126396 | The multifaceted role of glial cells in amyotrophic lateral sclerosis |
| Q37971725 | The neuroprotective effects of apocynin |
| Q92970041 | The role of NOX inhibitors in neurodegenerative diseases |
| Q38105903 | The role of inflammation in sporadic and familial Parkinson's disease |
| Q91860762 | The role of mutations associated with familial neurodegenerative disorders on blood-brain barrier function in an iPSC model |
| Q33633778 | The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis |
| Q39247056 | The seeds of neurodegeneration: prion-like spreading in ALS |
| Q37393810 | Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS |
| Q27015029 | Therapeutic neuroprotective agents for amyotrophic lateral sclerosis |
| Q34557892 | Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease. |
| Q38589482 | Translational potential of astrocytes in brain disorders |
| Q36394283 | Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. |
| Q92997182 | Treatment of a Mouse Model of ALS by In Vivo Base Editing |
| Q34714347 | What can pluripotent stem cells teach us about neurodegenerative diseases? |
| Q35019628 | Wild-type but not mutant SOD1 transgenic astrocytes promote the efficient generation of motor neuron progenitors from mouse embryonic stem cells |
| Q35204234 | Your brain under the microscope: the promise of stem cells |
| Q34250426 | iPSC-Derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1 |
| Q38766177 | iPSC-derived LewisX+CXCR4+β1-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. |
| Q41517672 | p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. |
| Q37017296 | α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy |
Search more.